257 related articles for article (PubMed ID: 29158137)
1. Recent developments in the management of bladder cancer: Introduction.
Smith AB
Urol Oncol; 2018 Mar; 36(3):95-96. PubMed ID: 29158137
[TBL] [Abstract][Full Text] [Related]
2. The Changing Treatment Landscape for Metastatic Urothelial Carcinoma.
Flaig TW
J Natl Compr Canc Netw; 2018 May; 16(5S):636-638. PubMed ID: 29784744
[TBL] [Abstract][Full Text] [Related]
3. Recent developments in the treatment of advanced bladder cancer.
Godwin JL; Hoffman-Censits J; Plimack E
Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma.
Siefker-Radtke AO; Apolo AB; Bivalacqua TJ; Spiess PE; Black PC
J Urol; 2018 May; 199(5):1129-1142. PubMed ID: 29113841
[TBL] [Abstract][Full Text] [Related]
5. Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?
Di Nunno V; Gatto L; Fragomeno B; Cubelli M; Nobili E; Romano I; Santoni M; Pisconti S; Montironi R; Massari F
Future Oncol; 2018 Dec; 14(29):2997-2999. PubMed ID: 30411632
[No Abstract] [Full Text] [Related]
6. Prostate cancer immunotherapy: where are we and where are we going?
De Velasco MA; Uemura H
Curr Opin Urol; 2018 Jan; 28(1):15-24. PubMed ID: 29095729
[TBL] [Abstract][Full Text] [Related]
7. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
Park JC; Hahn NM
Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
[TBL] [Abstract][Full Text] [Related]
8. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Gastrointestinal Carcinoma - How to Separate Hope from Hype.
Moehler M
Oncol Res Treat; 2018; 41(5):264-265. PubMed ID: 29705785
[No Abstract] [Full Text] [Related]
10. Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends.
Cheung PF; Lutz M; Siveke JT
Oncol Res Treat; 2018; 41(5):286-290. PubMed ID: 29705789
[TBL] [Abstract][Full Text] [Related]
11. Current status and limitations of immunotherapy for breast cancer.
Tokumaru Y; Joyce D; Takabe K
Surgery; 2020 Mar; 167(3):628-630. PubMed ID: 31623855
[No Abstract] [Full Text] [Related]
12. Perioperative systemic therapy for bladder cancer.
Eulitt PJ; Bjurlin MA; Milowsky MI
Curr Opin Urol; 2019 May; 29(3):220-226. PubMed ID: 30855376
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy.
Wang W; Zou W; Liu JR
Gynecol Oncol; 2018 Oct; 151(1):1-3. PubMed ID: 30243508
[No Abstract] [Full Text] [Related]
14. Innovation in Bladder Cancer Immunotherapy.
Grossman HB; Lamm DL; Kamat AM; Keefe S; Taylor JA; Ingersoll MA
J Immunother; 2016 Oct; 39(8):291-7. PubMed ID: 27428265
[TBL] [Abstract][Full Text] [Related]
15. CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.
Kranz LM; Beck JD; Grunwitz C; Hotz C; Vormehr M; Diken M
Hum Vaccin Immunother; 2017 Oct; 13(10):2272-2279. PubMed ID: 28846471
[No Abstract] [Full Text] [Related]
16. The latest treatment options for bladder cancer.
Crabb SJ; Douglas J
Br Med Bull; 2018 Dec; 128(1):85-95. PubMed ID: 30371744
[TBL] [Abstract][Full Text] [Related]
17. Women's cancer: Advancing molecular and immunotherapy.
Dorigo O
Curr Probl Cancer; 2017; 41(1):7. PubMed ID: 28366203
[No Abstract] [Full Text] [Related]
18. The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer.
Nair SS; Weil R; Dovey Z; Davis A; Tewari AK
Urol Clin North Am; 2020 Nov; 47(4S):e17-e54. PubMed ID: 33446323
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for kidney cancer: status quo and the future.
Bedke J; Stühler V; Stenzl A; Brehmer B
Curr Opin Urol; 2018 Jan; 28(1):8-14. PubMed ID: 29120911
[TBL] [Abstract][Full Text] [Related]
20. Making urothelial carcinomas less immune to immunotherapy.
Ramos JD; Yu EY
Urol Oncol; 2016 Dec; 34(12):534-537. PubMed ID: 27836245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]